Advertisement

Topics

Latest "Tranziger Limited" News Stories

12:52 EDT 15th October 2018 | BioPortfolio

Here are the most relevant search results for "Tranziger Limited" found in our extensive news archives from over 250 global news sources.

More Information about Tranziger Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tranziger Limited for you to read. Along with our medical data and news we also list Tranziger Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tranziger Limited Companies for you to search.

Showing "Tranziger Limited" News Articles 1–25 of 385

Relevant

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’...


Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET, in New York, NY. At the event, Franz Walt, Chief Executive Officer of Quotient Limited, along with other members of the management team, will provide a briefing on ...

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials. “I am very pleased to announce the start of our European field trials for...


Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim ...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of...

Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

Field trial concordance data exceed targeted criteriaPlanned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria ...

Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canad...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd, 2018 at 4:00 p.m. EDT at The InterContinental New York Barclay Hotel, in New York, NY.  ...

BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited

CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it attended a hearing before the Listing Committee of the Stock Exchange of Hong Kong Limited (“HKEx...

Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, July 24, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018, will be released after market close on Monday, August 6, 2018. Quotient will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. Eastern Time to discuss its f...

Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

MELBOURNE, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). The Agreement pr...

Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

MELBOURNE, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development & operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China vi...

Probably Relevant

Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility

Initial IH CE mark submission has been completed and filed on scheduleSuccessful facility audits pave the way for an on time BioCampus ramp up JERSEY, Channel Islands, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i) the submission of its completed dossier for the CE mark of its initial MosaiQ IH product as planned; ...

Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 15, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, will be released before market open on Tuesday, May 29, 2018. The Company will host a conference call to discuss its fourth quarter and fiscal full year financia...

Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction

Verification & Validation (“V&V”) “head-to-head” data exceeds target concordance for blood groupingOverall concordance for antigen typing – 99.8%, demonstrating robustness of the MosaiQ platformCompletion of the BioCampus sale and leaseback transaction JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diag...

Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ™ European Field Trials

MosaiQ European field trial which commenced on May 17, 2018 is ongoingFranz Walt is appointed as Chief Executive OfficerFourth quarter product revenues of $6.1 million, up 29.6% JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercialization of MosaiQ and financial resul...

Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results

$48.8 million of proceeds from warrant exercises received through July 31$36 million of additional senior notes issued and funded in JuneInitial SDS microarray verification and validation startedRecord reagent revenues recorded during the quarter JERSEY, Channel Islands, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (Quotient or the Company), a commercial-stage diagnostics ...

FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options

--Advisory committee supports surrogate endpoint of sputum culture conversion-- --ALIS currently under FDA Priority Review; PDUFA action date set for September 28, 2018-- BRIDGEWATER, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the U.S. Food and D...

Fagron NV : Disclosure of received notification

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2018 - 7:00am (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification. Notification of JPMorgan Asset Management Holdings Inc., received on 26 July 2018 On 26 July 2018, Fagron received a not...

Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative T

—Commercial availability expected in early Q4 2018— —Conference call scheduled for today at 6:15 PM ET— BRIDGEWATER, N.J., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...

Genetic Technologies Limited Announces Expansion of Genetic Risk Assessment Tests and October Launch of New Breast Cancer and Colorectal Cancer Tests

MELBOURNE, Australia, July 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that both its new breast cancer and colorectal cancer risk assessment tests are on track for release in October 2018.  In addition the company...

Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer

JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive Officer. Franz Walt, who recently retired as the President of Siemens Healthineers, Laboratory Diagnostics, and is a member of Quotient's Board of Directors, has been appointed as in...

The9 Limited Announces Unaudited Financial Information as of and for the Six Months Ended ...

THE9 LIMITED UNAUDITED CONSOLIDATED BALANCE SHEETS INFORMATION (Expressed in Renminbi - RMB and US Dollars - US$)  As of December 31, 2016 As of December Read more...

Global and Asia Instant Adhesive Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Terveystalo Plc: Disclosure under Chapter 9, Section 5 of the Securities Markets Act (EQT)

TERVEYSTALO PLC       STOCK EXCHANGE RELEASE    21 May 2018 at 9.10 a.m. EEST Terveystalo Plc ("Terveystalo" or the "Company") has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from EQT VI Limited. According to the notification, the total holdings in Terveystalo ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks